Laboratory Corporation of America Holdings (LH)
| Previous close | 200.25 |
| Open | 201.12 |
| Bid | 200.76 x 900 |
| Ask | 200.93 x 800 |
| Day's range | 199.68 - 202.92 |
| 52-week range | 179.59 - 234.09 |
| Volume | |
| Avg. volume | 795,953 |
| Market cap | 16.96B |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | 42.90 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.88 (1.44%) |
| Ex-dividend date | 28 May 2024 |
| 1y target est | N/A |
- PR Newswire
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene therapy.
- PR Newswire
Labcorp Announces 2024 First Quarter Results
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2024 and updated full-year guidance.
- PR Newswire
Labcorp Announces Winning Bid for Select Assets of Invitae
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.
